Does S100B have a potential role in affective disorders? A literature review

References

• Schmidt FM, Mergl R, Stach B, et al. Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE), but not S100B in major depressive disorder. World J Biol Psychiatry. 2015;16:106–113.
   PubMed Web of Science ®Google Scholar
• Jakobsson J, Bjerke M, Ekman CJ, et al. Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients. Neuropsychopharmacology. 2014;39:2349–2356.
   PubMed Web of Science ®Google Scholar
• Schroeter ML, Sacher J, Steiner J, et al. Serum S100B represents a new biomarker for mood disorders. Curr Drug Targets. 2013;14:1237–1248.
   PubMed Web of Science ®Google Scholar
• Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry. 2000;48:766–777.
   PubMed Web of Science ®Google Scholar
• Schroeter ML, Steiner J, Mueller K. Glial pathology is modified by age in mood disorders – a systematic meta-analysis of serum S100B in vivo studies. J Affect Disord. 2011;134:32–38.
   PubMed Web of Science ®Google Scholar
• Kalia M, Costa ESJ. Biomarkers of psychiatric diseases: current status and future prospects. Metabolism. 2015;64:S11–S15.
   PubMed Web of Science ®Google Scholar
• Davis J, Maes M, Andreazza A, et al. Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol Psychiatry. 2015;20:152–153.
   PubMed Web of Science ®Google Scholar
• Pinto JV, Moulin TC, Amaral OB. On the transdiagnostic nature of peripheral biomarkers in major psychiatric disorders: a systematic review. Neurosci Biobehav Rev. 2017;83:97–108.
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Peters M, Prehn JH, et al. S100B in brain damage and neurodegeneration. Microsc Res Tech. 2003;60:614–632.
   PubMed Web of Science ®Google Scholar
• Yelmo-Cruz S, Morera-Fumero AL, Abreu GP. S100B and schizophrenia. Psychiatry Clin Neurosci. 2013;67:67–75.
   PubMed Web of Science ®Google Scholar
• Undén L, Calcagnile O, Undén J, et al. Validation of the Scandinavian guidelines for initial management of minimal, mild and moderate traumatic brain injury in adults. BMC Med. 2015;13:292.
   PubMed Web of Science ®Google Scholar
• Falcone T, Janigro D, Lovell R, et al. S100B blood levels and childhood trauma in adolescent inpatients. J Psychiatr Res. 2015;62:14–22.
   PubMed Web of Science ®Google Scholar
• Cohen J. 1988. Statistical power analysis for the behavioural sciences. 2nd ed. Hillsdale (NJ): Lawrence Earlbaum Associates.
   Google Scholar
• Schroeter ML, Abdul-Khaliq H, Diefenbacher A, et al. S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport. 2002;13:1675–1678.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Lara DR, Portela LV, et al. Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study. Eur Neuropsychopharmacol. 2002;12:269–272.
   PubMed Web of Science ®Google Scholar
• Andreazza AC, Cassini C, Rosa AR, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res. 2007;41:523–529.
   PubMed Web of Science ®Google Scholar
• Tsai MC, Huang TL. Decreased S100B serum levels after treatment in bipolar patients in a manic phase. Compr Psychiatry. 2017;74:27–34.
   PubMed Web of Science ®Google Scholar
• Arolt V, Peters M, Erfurth A, et al. S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol. 2003;13:235–239.
   PubMed Web of Science ®Google Scholar
• Hetzel G, Moeller O, Evers S, et al. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology. 2005;178:161–166.
   PubMed Web of Science ®Google Scholar
• Schroeter ML, Abdul-Khaliq H, Krebs M, et al. Serum markers support disease-specific glial pathology in major depression. J Affect Disord. 2008;111:271–280.
   PubMed Web of Science ®Google Scholar
• Benitez A, Gunstad J, Hughes J, et al. Troponin and S100 beta are associated with depression in healthy older adults. Aging Ment Health. 2009;13:894–898.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Rothermundt M, Peters M, et al. S100B serum levels and word memory processing in remitted major depression as reflected by brain potentials. Neuropsychobiology. 2009;59:172–177.
   PubMed Web of Science ®Google Scholar
• Polyakova M, Sander C, Arelin K, et al. First evidence for glial pathology in late life minor depression: S100B is increased in males with minor depression. Front Cell Neurosci. 2015;9:406.
   PubMed Web of Science ®Google Scholar
• Dietrich DE, Hauser U, Peters M, et al. Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression. Neurosci Lett. 2004;354:69–73.
   PubMed Web of Science ®Google Scholar
• Yang K, Xie GR, Hu YQ, et al. The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression. J Neural Transm. 2008;115:1687–1694.
   PubMed Web of Science ®Google Scholar
• Jang BS, Kim H, Lim SW, et al. Serum S100B levels and major depressive disorder: its characteristics and role in antidepressant response. Psychiatry Investig. 2008;5:193–198.
   PubMed Web of Science ®Google Scholar
• Tsai MC, Huang TL. Increased activities of both superoxide dismutase and catalase were indicators of acute depressive episodes in patients with major depressive disorder. Psychiatry Res. 2016;235:38–42.
   PubMed Web of Science ®Google Scholar
• Grabe HJ, Ahrens N, Rose HJ, et al. Neurotrophic factor S100 beta in major depression. Neuropsychobiology. 2001;44:88–90.
   PubMed Web of Science ®Google Scholar
• Fang Y, Xiao SF, Zhang SY, et al. Increased plasma S100β level in patients with major depressive disorder. CNS Neurosci Ther. 2016;22:248–250.
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Arolt V, Wiesmann M, et al. S-100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord. 2001;66:89–93.
   PubMed Web of Science ®Google Scholar
• Moutsatsou P, Tsoporis JN, Salpeas V, et al. Peripheral blood lymphocytes from patients with bipolar disorder demonstrate apoptosis and differential regulation of advanced glycation end products and S100B. Clin Chem Lab Med. 2014;52:999–1007.
   PubMed Web of Science ®Google Scholar
• Rajewska-Rager A, Pawlaczyk M. The role of S100B protein as a potential marker in affective disorders. Psychiatr Pol. 2016;50:849–857.
   PubMed Web of Science ®Google Scholar
• da Rosa MI, Simon C, Grande AJ, et al. Serum S100B in manic bipolar disorder patients: systematic review and meta-analysis. J Affect Disord. 2016;206:210–215.
   PubMed Web of Science ®Google Scholar
• Patel JP, Frey BN. Disruption in the blood–brain barrier: the missing link between brain and body inflammation in bipolar disorder? Neural Plast. 2015;2015:708306.
   PubMed Web of Science ®Google Scholar
• Kapural M, Krizanac-Bengez L, Barnett G, et al. Serum S-100 beta as a possible marker of blood–brain barrier disruption. Brain Res. 2002;940:102–104.
   PubMed Web of Science ®Google Scholar
• Schroeter ML, Steiner J, Schonknecht P, et al. Further evidence for a role of S100B in mood disorders: a human gene expression mega-analysis. J Psychiatr Res. 2014;53:84–86.
   PubMed Web of Science ®Google Scholar
• Roche S, Cassidy F, Zhao C, et al. Candidate gene analysis of 21q22: support for S100B as a susceptibility gene for bipolar affective disorder with psychosis. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:1094–1096.
   PubMed Web of Science ®Google Scholar
• Wium-Andersen IK, Vinberg M, Kessing LV, et al. Personalized medicine in psychiatry. Nord J Psychiatry. 2017;71:12–19.
   PubMed Web of Science ®Google Scholar